Drug Profile


Alternative Names: allo-APZ2-CVU; allo-APZ2-DFU; ALLO-APZ2-PAOD; APZ2

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RHEACELL
  • Class Cell therapies; Skin disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action ATP-binding cassette transporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral arterial occlusive disorders; Varicose ulcer
  • Suspended Diabetic foot ulcer

Most Recent Events

  • 01 Nov 2017 RHEACELL GmbH initiates enrolment in a phase I/II trial for Varicose-ulcer in Germany (NCT03257098)
  • 21 Aug 2017 Phase-I/II clinical trials in Peripheral arterial occlusive disorders (In adults, In the elderly) in Germany (IM) (EudraCT2017-000235-14)
  • 07 Aug 2017 Phase-I/II clinical trials in Diabetic foot ulcer in Germany (Topical) (EudraCT2017-000234-57)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top